Complete set of 107 full clinical study reports are made available

Complete set of 107 full clinical study reports are made available Announcement Date: April 9, 2014

Data from: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children

http://dx.doi.org/10.5061/dryad.77471

Tamiflu, Relenza, and influenza: what the data do (or don’t) tell us? Dryad Data 2014


Tamiflu, Relenza, and influenza: what the data do (or don’t) tell us

The following is a guest post from Tom Jefferson of The Cochrane Collaboration, Peter Doshi of the University of Maryland and Carl Heneghan from the University of Oxford. We asked them to tell the story behind their recent Cochrane systematic review [1] and dataset in Dryad [2] which holds valuable lessons about the evidence-base on which major public health recommendations are decided.  -TJV

In the late 2000s, half the world was busy buying and stockpiling the neuraminidase inhibitors oseltamivir (Tamiflu, Roche) and zanamivir (Relenza, GSK) in fear of an influenza pandemic. (Read More)


Title Relenza (Zanamivir) Clinical Study Reports
Downloaded
Description Full set of clinical study reports for the neuraminidase inhibitor Relenza (Zanamivir) produced by GlaxoSmithKline and made available to the Cochrane collaboration for the production of their meta-analysis of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
Download Relenza.zip (532.2 Mb)
Download README.txt (8.83 Kb)
Details View File Details
Title Tamiflu (oseltamivir) clinical study reports
Downloaded
Description Full set of clinical study reports for the neuraminidase inhibitor Tamiflu (Oseltamivir) produced by Roche and made available to the Cochrane collaboration for the production of their meta-analysis of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
Download README.txt (2.84 Kb)
Download Tamiflu.zip (741.8 Mb)
Details View File Details